A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
📍 Aftermath
Vivani developed a semaglutide implant to improve long-term weight loss adherence for GLP-1 users. Novo Nordisk signed a pact with Vivani to evaluate the long-acting implant, which could last up to a year.
Epilogue added 30d ago, after coverage quieted.
Sources (5)
- Vivani develops semaglutide implant to improve long-term weight loss adherence for GLP-1 users Pluang · 32d ago
- Ozempic & Wegovy Maker To Evaluate Long-Acting GLP-1 Implant That Could Last Up To A Year Health and Me · 32d ago
- Biotech CEO on new Novo Nordisk partnership: “This could be big” medwatch.com · 32d ago
- Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant Yahoo Finance · 32d ago
- A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss CNBC · 32d ago broke it first
The brief
Novo Nordisk has entered into a formal agreement with the biotech firm Vivani. The companies are collaborating on the development of a tiny, implantable device intended to deliver semaglutide to patients over extended periods.
Coverage from outlets including CNBC, Yahoo Finance, and Pluang emphasizes the potential for the implant to improve treatment adherence for GLP-1 users. Reports note that the device is currently being evaluated for a duration that could potentially last up to a year.
Future updates are expected to track the progress of the partnership and the clinical development of the implant technology. Current coverage does not yet specify a timeline for potential regulatory submissions or human trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 32d ago.
Quick answers
What is the primary function of the new implant?
The implant is designed to deliver semaglutide to patients to help maintain weight loss and improve adherence to treatment.
Which companies are involved in this development?
Novo Nordisk and Vivani have signed a partnership agreement to develop the technology.
How long is the implant expected to last?
Current reports indicate that the device is being evaluated to potentially last up to a year.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
Compounded GLP-1 drugs creating concern among doctors and FDA
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
Weight-loss jab users warned about relationship side effect no one prepares you for
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.